First human test for new fatty liver drug begins
NCT ID NCT06836609
Summary
This is an early-stage study to test the safety of an experimental drug called ALN-CIDEB in adults with fatty liver disease (MASLD and MASH). The main goal is to see what side effects occur and how the body processes the drug. Researchers will also check if the drug reduces liver fat using special MRI scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Parexel International Early Phase Clinical Unit
RECRUITINGHarrow, London, HA1 3UJ, United Kingdom
-
Richmond Pharmacology Limited
RECRUITINGLondon, Greater London, SE1 1YR, United Kingdom
Conditions
Explore the condition pages connected to this study.